Advanced glycation end-products: Modifiable environmental factors profoundly mediate insulin resistance

Journal of Clinical Biochemistry and Nutrition

Volumn 57, Issue 1, 2015, Pages 1-12

  Ottum, Mona S ^a   Mistry, Anahita M ^a  

^a EASTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

AGEs; Glycation; Insulin resistance; Oxidative stress; Western diet

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUTATHIONE; INSULIN; REACTIVE NITROGEN SPECIES; SUPEROXIDE DISMUTASE; THIOREDOXIN;

DIET; ENERGY BALANCE; ENVIRONMENTAL FACTOR; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDOX STRESS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 84938413696     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.15-3     Document Type: Review

References (184)

1. Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA; Centers for Desease Control and Prevention (CDC). CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors-United States, 2005-2013. MMWR Surveill Summ 2014; 63 Suppl 4: 3-27
2. Thorpe KE. Treated disease prevalence and spending per treated case drove most of the growth in health care spending in 1987-2009. Health Aff (Millwood) 2013; 32: 851-858
3. Hellgren MI, Daka B, Jansson PA, Lindblad U, Larsson CA. Insulin resistance predicts early cardiovascular morbidity in men without diabetes mellitus, with effect modification by physical activity. Eur J Prev Cardiol 2014. DOI: 10.1177/2047487314537917
4. Morris JK, Vidoni ED, Perea RD, et al. Insulin resistance and gray matter volume in neurodegenerative disease. Neuroscience 2014; 270: 139-147
5. Krentz AJ, Viljoen A, Sinclair A. Insulin resistance: a risk marker for disease and disability in the older person. Diabet Med 2013; 30: 535-548
6. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011; 378: 169-181
7. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22 Suppl 1: S20-S27
8. Valko M, Leibfritz D, Moncol J, Cronin M, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84
9. Pitocco D, Zaccardi F, Stasio E, et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabetic Stud 2010; 7: 15-25
10. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-295
11. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 2011; 194: 7-15
12. Yao H, Sundar IK, Ahmad T, et al. SIRT1 protects against cigarette smokeinduced lung oxidative stress via a FOXO3-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2014; 306: L816-L828
13. Diamond-Stanic MK, Marchionne EM, Teachey MK, Durazo DE, Kim JS, Henriksen EJ. Critical role of the transient activation of p38 MAPK in the etiology of skeletal muscle insulin resistance induced by low-level in vitro oxidant stress. Biochem Biophys Res Commun 2011; 405: 439-444
14. Sato A, Okada M, Shibuya K, et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res 2014; 12: 119-131
15. Ou X, Lee MR, Huang X, Messina-Graham S, Broxmeyer HE. SIRT1 positively regulates autophagy and mitochondria function in embryonic stem cells under oxidative stress. Stem Cells 2014; 32: 1183-1194
16. Yang L, Zhang J, Yan C, et al. SIRT1 regulates CD40 expression induced by TNF-α via NF-κB pathway in endothelial cells. Cell Physiol Biochem 2012; 30: 1287-1298
17. Salminen A, Kaarniranta K, Kauppinen A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int J Mol Sci 2013; 14: 3834-3859
18. Ren JH, Tao Y, Zhang ZZ, et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol 2014; 88: 2442-2451
19. Bononi A, Agnoletto C, De Marchi E, et al. Protein kinases and phosphatases in the control of cell fate. Enzyme Res 2011; 2011: 329098
20. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005; 97: 967-974
21. Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 2008; 10: 179-206
22. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003; 17: 24-38
23. Diaz Vivancos P, Wolff T, Markovic J, Pallardó FV, Foyer CH. A nuclear glutathione cycle within the cell cycle. Biochem J 2010; 431: 169-178
24. Burke-Gaffney A, Callister ME, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 2005; 26: 398-404
25. Holmgren A, Lu J. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun 2010; 396: 120-124
26. Miranda-Vizuete A, Damdimopoulos AE, Spyrou G. The mitochondrial thioredoxin system. Antioxid Redox Signal 2000; 2: 801-810
27. Kong L, Zhou X, Li F, Yodoi J, McGinnis J, Cao W. Neuroprotective effect of overexpression of thioredoxin on photoreceptor degeneration in Tubby mice. Neurobiol Dis 2010; 38: 446-455
28. Fabbrini E, Serafini M, Colic Baric, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes 2014; 63: 976-981
29. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003; 44: 512-521
30. Nyyssönen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis 1997; 130: 223-233
31. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology (Oxford) 2010; 49: 1229-1238
32. Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004; 1: 10
33. Kang DH, Ha SK. Uric acid puzzle: dual role as anti-oxidant and prooxidant. Electrolyte Blood Press 2014; 12: 1-6
34. Alcaino H, Greig D, Chiong M, et al. Serum uric acid correlates with extracellular superoxide dismutase activity in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 646-651
35. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7
36. Torralba KD, De Jesus E, Rachabattula S. The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. Int J Rheum Dis 2012; 15: 499-506
37. Wang Y, Yan S, Li C, et al. Risk factors for gout developed from hyperuricemia in China: a five-year prospective cohort study. Rheumatol Int 2013; 33: 705-710
38. Chang WC. Dietary intake and the risk of hyperuricemia, gout and chronic kidney disease in elderly Taiwanese men. Aging Male 2011; 14: 195-202
39. Zgaga L, Theodoratou E, Kyle J, et al. The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One 2012; 7: e38123
40. Haidari F Jr, Mohammad Shahi, Keshavarz SA, Rashidi MR. Inhibitory effects of tart cherry (Prunus cerasus) juice on xanthine oxidoreductase activity and its hypouricemic and antioxidant effects on rats. Malays J Nutr 2009; 15: 53-64
41. Edeas M, Attaf D, Mailfert AS, Nasu M, Joubet R. Maillard reaction, mitochondria and oxidative stress: potential role of antioxidants. Pathol Biol (Paris) 2010; 58: 220-225
42. Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. Arterioscler Thromb Vasc Biol 2004; 24: 1367-1373
43. Liebler DC, Kling DS, Reed DJ. Antioxidant protection of phospholipid bilayers by alpha-tocopherol. Control of alpha-tocopherol status and lipid peroxidation by ascorbic acid and glutathione. J Biol Chem 1986; 261: 12114-12119
44. Liu M, Wallin R, Wallmon A, Saldeen T. Mixed tocopherols have a stronger inhibitory effect on lipid peroxidation than alpha-tocopherol alone. J Cardiovasc Pharmacol 2002; 39: 714-721
45. Wu CM, Cheng YL, Dai YH, Chen MF, Wang CC. α-Tocopherol protects keratinocytes against ultraviolet A irradiation by suppressing glutathione depletion, lipid peroxidation and reactive oxygen species generation. Biomed Rep 2014; 2: 419-423
46. Rodrigues E, Mariutti LR, Mercadante AZ. Scavenging capacity of marine carotenoids against reactive oxygen and nitrogen species in a membranemimicking system. Mar Drugs 2012; 10: 1784-1798
47. Baraibar MA, Ladouce R, Friguet B. Proteomic quantification and identification of carbonylated proteins upon oxidative stress and during cellular aging. J Proteomics 2013; 92: 63-70
48. Rabbani N, Thornalley PJ. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress. Biochem Soc Trans 2008; 36: 1045-1050
49. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 2011; 143: 58-65
50. Semba RD, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol Series A: Biolog Sci Med Sci 2010; 65: 963-975
51. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21
52. Jennings BJ, Ozanne SE, Hales CN. Nutrition, oxidative damage, telomere shortening, and cellular senescence: individual or connected agents of aging? Mol Genet Metab 2000; 71: 32-42
53. Paul L. Diet, nutrition and telomere length. J Nutr Biochem 2011; 22: 895-901
54. Speakman JR, Hambly C. Starving for life: what animal studies can and cannot tell us about the use of caloric restriction to prolong human lifespan. J Nutr 2007; 137: 1078-1086
55. Cai W, He JC, Zhu L, et al. Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008; 173: 327-336
56. Luevano-Contreras C, Chapman-Novakofski K. Dietary advanced glycation end products and aging. Nutrients 2010; 2: 1247-1265
57. de la Maza MP, Uribarri J, Olivares D, et al. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. Rejuvenation Res 2008; 11: 1041-1048
58. Gugliucci A, Kotani K, Taing J, et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009; 54: 197-201
59. Stuart JA, Maddalena LA, Merilovich M, Robb EL. A midlife crisis for the mitochondrial free radical theory of aging. Longev Healthspan 2014; 3: 4
60. Labunskyy VM, Gerashchenko MV, Delaney JR, et al. Lifespan extension conferred by endoplasmic reticulum secretory pathway deficiency requires induction of the unfolded protein response. PLoS Genet 2014; 10: e1004019
61. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal 2007; 9: 2277-2293
62. Caron AZ, He X, Mottawea W, et al. The SIRT1 deacetylase protects mice against the symptoms of metabolic syndrome. Faseb J 2014; 28: 1306-1316
63. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 2009; 389: 211-216
64. Giorgi C, Agnoletto C, Baldini C, et al. Redox control of protein kinase C: cell- and disease-specific aspects. Antioxid Redox Signal 2010; 13: 1051-1085
65. Gopalakrishna R, Jaken S. Protein kinase C signaling and oxidative stress. Free Radic Biol Med 2000; 28: 1349-1361
66. Rimessi A, Rizzuto R, Pinton P. Differential recruitment of PKC isoforms in HeLa cells during redox stress. Cell Stress Chaperones 2007; 12: 291-298
67. Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013; 25: 1939-1948
68. Jung TW, Lee KT, Lee MW, Ka KH. SIRT1 attenuates palmitate-induced endoplasmic reticulum stress and insulin resistance in HepG2 cells via induction of oxygen-regulated protein 150. Biochem Biophys Res Commun 2012; 422: 229-232
69. Xu C, Bai B, Fan P, et al. Selective overexpression of human SIRT1 in adipose tissue enhances energy homeostasis and prevents the deterioration of insulin sensitivity with ageing in mice. Am J Transl Res 2013; 5: 412-426
70. Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem 2008; 19: 491-504
71. O'Brien J, Morrissey PA. Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 1989; 28: 211-248
72. Bengmark S. Advanced glycation and lipoxidation end products-amplifiers of inflammation: the role of food. JPEN J Parenter Enteral Nutr 2007; 31: 430-440
73. Chuyen NV. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs. Mol Nutr Food Res 2006; 50: 1140-1149
74. Mortensen HB. Glycated hemoglobin. Reaction and biokinetic studies. Clinical application of hemoglobin A1c in the assessment of metabolic control in children with diabetes mellitus. Dan Med Bull 1985; 32: 309-328
75. Hindle EJ, Rostron GM, Gatt JA. The diagnostic value of glycated haemoglobin levels in post-mortem blood. Ann Clin Biochem 1985; 22 (Pt 2): 144-147
76. Xanthis A, Hatzitolios A, Koliakos G, Tatola V. Advanced glycosylation end products and nutrition-a possible relation with diabetic atherosclerosis and how to prevent it. J Food Sci 2007; 72: R125-R129
77. Yamagishi S. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009; 13: 534-539
78. Takeuchi M, Takino J, Yamagishi S. Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy. J Ophthalmol 2010; 2010: 170393
79. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146
80. Miyata T, Kurokawa K, Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate metabolism. J Am Soc Nephrol 2000; 11: 1744-1752
81. Leuner B, Max M, Thamm K, et al. RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet. Z Gerontol Geriatr 2012; 45: 102-108
82. Monnier VM, Sun W, Sell DR, Fan X, Nemet I, Genuth S. Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clin Chem Lab Med 2014; 52: 21-32
83. Poulsen MW, Hedegaard RV, Andersen JM, et al. Advanced glycation endproducts in food and their effects on health. Food Chem Toxicol 2013; 60: 10-37
84. Busch M, Franke S, Rüster C, Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest 2010; 40: 742-755
85. Vlassara H, Uribarri J, Cai W, Striker G. Advanced glycation end product homeostasis. Ann N Y Acad Sci 2008; 1126: 46-52
86. Su XD, Li SS, Tian YQ, Zhang ZY, Zhang GZ, Wang LX. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes. Arch Med Res 2011; 42: 596-601
87. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999; 22: 1543-1548
88. Masoro EJ, Katz MS, McMahan CA. Evidence for the glycation hypothesis of aging from food-restricted rodent model. J Gerontol 1989; 44: B20-B22
89. Sensi M, Pricci F, Andreani D, Di Mario U. Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications. Diabetes Res 1991; 16: 1-9
90. Karasu C. Glycoxidative stress and cardiovascular complications in experimentally- induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J 2010; 4: 240-256
91. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006; 131: 934-945
92. Ye J. Mechanisms of insulin resistance in obesity. Front Med 2013; 7: 14-24
93. Kumar R, Prakash S, Chhabra S, et al. Association of pro-inflammatory cytokines, adipokines & oxidative stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res 2012; 136: 229-236
94. Santos JC, Valentim IB, de Araujo OR, Ataide Tda R, Goulart MO. Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products. Int J Mol Sci 2013; 14: 19846-19866
95. Lima FD, Stamm DN, Della-Pace ID, et al. Swimming training induces liver mitochondrial adaptations to oxidative stress in rats submitted to repeated exhaustive swimming bouts. PLoS One 2013; 8: e55668
96. Hagopian K, Harper ME, Ram JJ, Humble SJ, Weindruch R, Ramsey JJ. Long-term calorie restriction reduces proton leak and hydrogen peroxide production in liver mitochondria. Am J Physiol Endocrinol Metab 2005; 288: E674-E684
97. Ascensão A, Martins MJ, Santos-Alves E, et al. Modulation of hepatic redox status and mitochondrial metabolism by exercise: therapeutic strategy for liver diseases. Mitochondrion 2013; 13: 862-870
98. Coen PM, Hames KC, Leachman EM, et al. Reduced skeletal muscle oxidative capacity and elevated ceramide but not diacylglycerol content in severe obesity. Obesity (Silver Spring) 2013; 21: 2362-2371
99. Leung C, Herath CB, Jia Z, et al. Dietary glycotoxins exacerbate progression of experimental fatty liver disease. J Hepatol 2014; 60: 832-838
100. Barnard RJ, Roberts CK, Varon SM, Berger JJ. Diet-induced insulin resistance precedes other aspects of the metabolic syndrome. J Appl Physiol (1995) 1998; 84: 1311-1315
101. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome. Metabolism 2006; 55: 928-934
102. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, Hotta N. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 1996; 228: 539-543
103. Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol 2012; 3: 87
104. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. Faseb J 1999; 13: 23-30
105. Tang WH, Cheng WT, Kravtsov GM, et al. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathwaymediated oxidative stress. Am J Physiol Cell Physiol 2010; 299: C643-C653
106. Chung SS, Ho EC, Lam KS, Chung SK. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 2003; 14 (8 Suppl 3): S233-S236
107. Srivastava SK, Ansari NH, Hair GA, Jaspan J, Rao MB, Das B. Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties. Biochim Biophys Acta 1986; 870: 302-311
108. Schalkwijk CG, Stehouwer CDA, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabet Metab Res Rev 2004; 20: 369-382
109. Varma SD, Schocket SS, Richards RD. Implications of aldose reductase in cataracts in human diabetes. Invest Ophthalmol Vis Sci 1979; 18: 237-241
110. Lerner BC, Varma SD, Richards RD. Polyol pathway metabolites in human cataracts. Correlation of circulating glycosylated hemoglobin content and fasting blood glucose levels. Arch Ophthalmol 1984; 102: 917-920
111. Dyck PJ, Zimmerman BR, Vilen TH, et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988; 319: 542-548
112. Mayhew JA, Gillon KR, Hawthorne JN. Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983; 24: 13-15
113. Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGERAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010; 9: 776-784
114. Nseir W, Nassar F, Assy N. Soft drinks consumption and nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 2579-2588
115. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol 2009; 51: 918-924
116. Crescenzo R, Bianco F, Falcone I, Coppola P, Liverini G, Iossa S. Increased hepatic de novo lipogenesis and mitochondrial efficiency in a model of obesity induced by diets rich in fructose. Eur J Nutr 2013; 52: 537-545
117. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334
118. Mastrocola R, Collino M, Rogazzo M, et al. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. Am J Physiol Gastrointest Liver Physiol 2013; 305: G398-G407
119. Lee O, Bruce WR, Dong Q, Bruce J, Mehta R, O'Brien PJ. Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact 2009; 178: 332-339
120. Takino J, Kobayashi Y, Takeuchi M. The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. J Gastroenterol 2010; 45: 646-655
121. Ebata Y, Takino J, Tsuchiya H, et al. Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice. Int J Vitam Nutr Res 2013; 83: 137-141
122. Kitahara Y, Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S Glyceraldehyde-derived advanced glycation end products (AGEs). A novel biomarker of postprandial hyperglycaemia in diabetic rats. Clin Exp Med 2008; 8: 175-177
123. Choei H, Sasaki N, Takeuchi M, et al. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease. Acta Neuropathol 2004; 108: 189-193
124. Usui T, Shizuuchi S, Watanabe H, Hayase F. Cytotoxicity and oxidative stress induced by the glyceraldehyde-related Maillard reaction products for HL-60 cells. Biosci Biotechnol Biochem 2004; 68: 333-340
125. Hamada Y, Nakamura J, Naruse K, et al. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nω-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539-1544
126. Coleman NJ, Miernik J, Philipson L, Fogelfeld L. Lean versus obese diabetes mellitus patients in the United States minority population. J Diabetes Complications 2014; 28: 500-505
127. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Poc Natl Acad Sci U S A 1997; 94: 6474-6479
128. He C, Sabol J, Mitsuhashi T, Vlassara H. Dietary glycotoxins: inhibition of reactive products by aminoquanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 1999; 48: 1308-1315
129. Uribarri J, Woodruff S, Goodman S, et al. Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-916.e12
130. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-1291
131. Tessier FJ, Birlouez-Aragon I. Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 2012; 42: 1119-1131
132. Birlouez-Aragon I, Morales F, Fogliano V, Pain JP. The health and technological implications of a better control of neoformed contaminants by the food industry. Pathol Biol (Paris) 2010; 58: 232-238
133. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stressinducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002; 8: 337-346
134. Marko D, Habermeyer M, Kemény M, et al. Maillard reaction products modulating the growth of human tumor cells in vitro. Chem Res Toxicol 2003; 16: 48-55
135. Hiramoto S, Itoh K, Shizuuchi S, et al. Melanoidin, a food protein-derived advanced maillard reaction product, suppresses Helicobacter pylori in vitro and in vivo. Helicobacter 2004; 9: 429-435
136. Borrelli RC, Visconti A, Mennella C, Anese M, Fogliano V. Chemical characterization and antioxidant properties of coffee melanoidins. J Agric Food Chem 2002; 50: 6527-6533
137. Dittrich R, El-Massry F, Kunz K, et al. Maillard reaction products inhibit oxidation of human low-density lipoproteins in vitro. J Agric Food Chem 2003; 51: 3900-3904
138. Borrelli RC, Fogliano V. Bread crust melanoidins as potential prebiotic ingredients. Mol Nutr Food Res 2005; 49: 673-678
139. Bacchetti T, Masciangelo S, Armeni T, Bicchiega V, Ferretti G. Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity. Metabolism 2014; 63: 307-311
140. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731
141. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004; 43: 690-695
142. Ueda S, Yamagishi S, Takeuchi M, et al. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol Med 2006; 12: 180-184
143. Mott JD, Khalifah RG, Nagase H, Shield CF 3rd, Hudson JK, Hudson BG. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int 1997; 52: 1302-1312
144. Pugliese G, Pricci F, Romeo G, et al. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 1997; 46: 1881-1887
145. Cai W, He JC, Zhu L, Lu C, Vlassara H. Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Nati Acad Sci U S A 2006; 103: 13801-13806
146. Cai W, Torreggiani M, Zhu L, et al. AGER1 regulates endothelial cell NADPH oxidase-dependent oxidant stress via PKC-delta: implications for vascular disease. Am J Physiol Cell Physiol 2010; 298: C624-C634
147. Uribarri J, Cai W, Ramdas M, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011; 34: 1610-1616
148. Cai W, He JC, Zhu L, et al. Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 2007; 170: 1893-1902
149. Zhu W, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Biophys Res Commun 2001; 280: 1183-1188
150. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009; 2: re3
151. Greaves DR, Gordon S. The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges. J Lipid Res 2009; 50 Suppl: S282-S286
152. Cassese A, Esposito I, Fiory F, et al. In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem 2008; 283: 36088-36099
153. Gaens KH, Goossens GH, Niessen PM, et al. Nω-(carboxymethyl)lysine receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol 2014; 34: 1199-1208
154. Warboys CM, Toh HB, Fraser PA. Role of NADPH Oxidase in retinal microvascular permeability increase by RAGE activation. Invest Ophthalmol Vis Sci 2009; 50: 1319-1328
155. Hofmann SM, Dong HJ, Li Z, et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002; 51: 2082-2089
156. Peppa M, He C, Hattori M, McEvoy R, Zheng F, Vlassara H. Fetal or neonatal low-glycotoxin environment prevent autoimmune diabetes in NOD mice. Diabetes 2003; 52: 1441-1448
157. Peppa M, Brem H, Ehrlich P, et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52: 2805-2813
158. Zheng F, He C, Cai W, Hattori M, Steffes M, Vlassara H. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002; 18: 224-237
159. Feng JX, Hou FF, Liang M, et al. Restricted intake of dietary advanced glycation end products retards renal progression in the remnant kidney model. Kidney Int 2007; 71: 901-911
160. Lin RY, Reis ED, Dore AT, et al. Lowering of dietary advanced glycation endproducts (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis 2002; 163: 303-311
161. Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003; 168: 213-220
162. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 2012; 109: 15888-15893
163. Sandu O, Song K, Cai W, Zheng F, Uribarri J, Vlassara H. Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake. Diabetes 2005; 54: 2314-2319
164. Chatzigeorgiou A, Kandaraki E, Piperi C, et al. Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol 2013; 218: 331-337
165. Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013; 28: 777-784
166. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69: 634-641
167. Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta 2014; 1842: 1693-1706
168. Cai W, Uribarri J, Zhu L, et al. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 2014; 111: 4940-4945
169. Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1α and MCP-1 levels in type 2 diabetic patients. Eur J Nutr 2010; 49: 429-434
170. Forbes JM, Sourris KC, de Courten MP, et al. Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids 2014; 46: 321-326
171. Gradinaru D, Borsa C, Ionescu C, Margina D. Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics 2013; 92: 313-322
172. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Nat Acad Sci U S A 2002; 99: 15596-15601
173. Luévano-Contreras C, Garay-Sevilla ME, Wrobel K, Malacara JM, Wrobel K. Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 2013; 52: 22-26
174. Cai W, He JC, Zhi L, et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-291
175. Negrean M, Stirban A, Stratmann B, et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-1243
176. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071
177. Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007; 30: 2579-2582
178. Vlassara H, Cai W, Goodman S, et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94: 4483-4491
179. Uribarri J, Cai W, Peppa M, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433
180. Mark AB, Poulsen MW, Andersen S, et al. Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 2014; 37: 88-95
181. Uribarri J, Cai W, Pyzik R, et al. Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases. Amino Acids 2014; 46: 301-309
182. Birlouez-Aragon I, Saavedra G, Tessier FJ, et al. A diet based on high-heattreated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010; 91: 1220-1226
183. Mericq V, Piccardo C, Cai W, et al. Maternally transmitted and food-derived glycotoxins: a factor preconditioning the young to diabetes? Diabetes Care 2010; 33: 2232-2237
184. Tantalaki E, Piperi C, Livadas S, et al. Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 2014; 13: 65-73